BBNXBeta Bionics Inc. Common Stock

Pharmacy channel sales surged 153% as new patient starts accelerated.

Moby summary of Beta Bionics, Inc.'s Q2 2026 earnings call

Beta Bionics (NASDAQ:BBNX) reported second-quarter 2026 net sales of $32 million, up approximately 38% from a year earlier, as new patient starts and recurring pharmacy-channel supply revenue supported growth for its iLet insulin-delivery system. Chief Executive Officer Sean Saint said the company’

Beta Bionics, Inc. (BBNX) delivered earnings and revenue surprises of +14.52% and +2.07%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

The fair value estimate for Beta Bionics has moved from US$31.30 to US$19.80 per share, which places it closer to the current cluster of analyst price targets between US$13 and US$22. Recent commentary links this reset to a balance between optimism around iLet and the planned Mint launch, and caution related to medtech valuation resets and sector headwinds. As you read on, you will see how this shifting narrative and new assumptions might shape how you track Beta Bionics from here. Analyst...

Kestra Medical Technologies develops advanced wearable cardiac devices and digital health solutions for cardiovascular care providers.

Exploring the Latest 13F Filing and Investment Strategies

Beta Bionics (NASDAQ:BBNX) Chief Financial Officer Stephen Feider said the company’s first-quarter outperformance was supported by increasing use of the pharmacy reimbursement channel, expanded sales coverage and growing confidence in the company’s iLet insulin pump platform. Speaking at a Bank of

We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...